LONDON Michael Woodford, the CEO-turned-whistleblower at Japan's Olympus Corp., said he is winning the backing of major institutional investors willing to buy stock and back his campaign to regain control of the disgraced endoscope maker.
Speaking after a company-appointed panel delivered a damning verdict on how top managers bled Olympus of $1.7 billion in one of Japan's worst corporate scandals, Woodford said investors were flocking to meet him.
"Big, big, big names are travelling the world to see me," he told Reuters.
"I met some in New York on Friday and others are coming to London. And I might have to return to Japan in the coming days, it depends."
He declined to identify his contacts, saying only they were "potential shareholders".
Despite his sacking on October 14 for querying a series of odd-looking acquisitions and fees, Woodford remained a company director while launching a one-man campaign to urge prosecutors, regulators and journalists around the globe to investigate.
He finally resigned last week to free himself, he says, of corporate shackles that prevented him from contacting new investors in his quest to oust the current board and lead Olympus back to financial strength.
The scandal, that could yet spell a delisting if once-venerable Olympus fails to meet a December 14 deadline for reporting results or if the money trail leads prosecutors to Japanese gangsters, has sent the group's stock plunging up to 80 percent.
But investor hopes that Olympus will avoid that step if its boardroom and books are cleansed has sparked a rebound for a company whose robust core diagnostic endoscope business accounts for around 70 percent of the global market.
Woodford said he did not believe new investors such as Wall Street giant Goldman Sachs (GS.N), which snapped up a near 7 percent stake in November, were trying to turn a quick profit on the company's misfortunes.
"I've spoken to people whom Goldman has bought the stock for," he said.
"I don't forsee Olympus being sold or anything like that happening. Those interested in taking a stake see a company that will have a renaissance -- and support a new strong management with me and others."
Market experts say more than 50 percent of Olympus's stock is now likely to be held outside Japan -- although Tokyo-based hedge fund Tower Investment Management has bought a chunky 5.95 percent Olympus stake, according to a regulatory filing.
"I think it's a very dynamic situation," Woodford said. "But I think overwhelmingly those outside Japan support me." He added he would ideally like Japanese institutional support too.
A fresh trip to Tokyo -- which would be his second since he fled the country in October after being warned he might be in danger from organised crime -- would allow face-to-face meetings with Japanese investors.
"It's much easier if they can see me," said Woodford, who cut his teeth at Olympus over 30 years ago.
Rarely for a foreigner, he rose to the ranks of president in April and CEO in October. He says he feels such loyalty to the company he has funded his significant travel and legal bills from his own pocket.
Large western shareholders such as Southeastern Asset Management and Harris Associates of the United States and Scotland's Baillie Gifford, have long called for a shareholder meeting to oust the board and reinstate Woodford.
But an extraordinary shareholder meeting can only be called by the company's board or by investors owning at least three percent of the company in their own name. Big western shareholders have invested largely on behalf of clients.
However, with the independent panel on Tuesday accusing the Olympus board of being riddled with a "tribal culture of the Japanese salaryman" after failing to grill the three executives who have admitted orchestrating the scam, Woodford believes the board can now do little but call for its own demise.
"The company, I think, will call an EGM," he said.
Woodford has spoken in the past of a group of talented Olympus managers he trusts who sit just below the board. Asked whether these, or others, were lined up to take up any empty seats, he said: "In an executive sense, yes. They havent signed on the dotted line, but I'm sure they would be (willing), yes."
(Editing by David Cowell)
FDA warns former Sun Pharma U.S. drug factory over quality concerns
MUMBAI The U.S. Food and Drug Administration has pulled up a former Sun Pharmaceutical drug factory for "knowingly" releasing 27 lots of the hypertension drug clonidine last year, despite proof that the raw materials used may have been contaminated.
Sensex posts worst weekly fall in nearly four months; Fed awaited
The BSE Sensex posted its worst week since early May on Friday, as investors stayed on the sidelines ahead a speech by U.S. Federal Reserve Chair Janet Yellen in Jackson Hole, Wyoming later in the day.
Fed's Mester: Makes sense for U.S. to start raising rates - CNBC
The U.S. Federal Reserve should hike rates again so as not to fall behind in a strengthening economy, Cleveland Fed President Loretta Mester said on Friday.